This Plain Language Summary of Publication article (PLSP) from Future Oncology tested avutometinib alone and combined with defactinib in patients with recurrent low-grade serous ovarian cancer after surgery and chemotherapy. Researchers measured how many patients’ tumors shrank by at least 30% for 2+ months, monitored safety, and tested for KRAS mutations to determine the most effective treatment approach.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201’ and was published in the Journal of Clinical Oncology.

Visit ASCO Publications using the link to read the original article.